Defence Therapeutics Announces Convertible Debenture Conversion
Defence Therapeutics (OTCQB:DTCFF) announced that holders of its 8% convertible debentures issued November 16, 2024, converted all principal and accrued interest into common shares upon maturity on November 16, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Defence Therapeutics (OTCQB:DTCFF) announced that holders of its 8% convertible debentures issued November 16, 2024, converted all principal and accrued interest into common shares upon maturity on November 16, 2025.
The principal amount of $1,476,000 converted into 2,460,000 shares at a conversion price of $0.60 per share, and $118,080 of accrued interest converted into 147,600 shares at $0.80 per share, totalling 2,607,600 shares and an aggregate amount of $1,594,080.
Positive
- Debt extinguished: $1,594,080 converted to equity
- Total new shares issued: 2,607,600 common shares
- Conversion settled on maturity: November 16, 2025
Negative
- Share issuance 2,607,600 may dilute existing shareholders
- Conversion price as low as $0.60 for principal
Details
News Market Reaction – DTCFF
On Nov 24, the first trading day after this news, DTCFF closed 2.99% above the previous close.
Data tracked by StockTitan Argus for the Nov 24 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Montreal, Quebec--(Newsfile Corp. - November 21, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), announces that the holders of the Corporation's
In accordance with the terms of the Debentures, the principal amount of
About Defence:
Defence Therapeutics is a publicly-traded biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275602
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.